NewLink Genetics Corporation (NASDAQ:NLNK) has been assigned an average rating of “Buy” from the eight analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $25.83.

Several analysts have weighed in on NLNK shares. Zacks Investment Research downgraded NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Jefferies Group LLC reiterated a “hold” rating and issued a $7.00 price objective on shares of NewLink Genetics Corporation in a research report on Friday, July 14th. Cantor Fitzgerald set a $26.00 price objective on NewLink Genetics Corporation and gave the company a “buy” rating in a research report on Friday, July 28th. ValuEngine downgraded NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Robert W. Baird upgraded NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $8.00 to $22.00 in a research report on Friday, September 8th.

In related news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the stock in a transaction on Friday, October 6th. The stock was purchased at an average price of $10.25 per share, for a total transaction of $7,999,991.75. Following the completion of the transaction, the insider now owns 7,857,732 shares of the company’s stock, valued at approximately $80,541,753. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 13.70% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of NewLink Genetics Corporation by 5.6% during the first quarter. Vanguard Group Inc. now owns 959,883 shares of the biotechnology company’s stock valued at $23,134,000 after acquiring an additional 51,013 shares in the last quarter. Columbus Circle Investors raised its holdings in shares of NewLink Genetics Corporation by 72.5% during the second quarter. Columbus Circle Investors now owns 591,765 shares of the biotechnology company’s stock valued at $4,349,000 after acquiring an additional 248,724 shares in the last quarter. State Street Corp raised its holdings in shares of NewLink Genetics Corporation by 1.2% during the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock valued at $2,875,000 after acquiring an additional 4,630 shares in the last quarter. Northern Trust Corp raised its holdings in shares of NewLink Genetics Corporation by 4.0% during the second quarter. Northern Trust Corp now owns 298,738 shares of the biotechnology company’s stock valued at $2,195,000 after acquiring an additional 11,532 shares in the last quarter. Finally, Teachers Advisors LLC raised its holdings in shares of NewLink Genetics Corporation by 3.0% during the first quarter. Teachers Advisors LLC now owns 207,854 shares of the biotechnology company’s stock valued at $5,009,000 after acquiring an additional 6,047 shares in the last quarter. Institutional investors own 55.09% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/02/newlink-genetics-corporation-nlnk-given-average-rating-of-buy-by-analysts.html.

NewLink Genetics Corporation (NASDAQ:NLNK) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.76) by $0.07. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.